Physician profile
Javed Imam
NPI 1548271380
$4,320.93
in general payments reported to CMS, 2019-2025
41 companies · $635 in 2025
The $635 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,018 · 2020: $819 · 2022: $82.14 · 2023: $231 · 2024: $537 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,402.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $754.44 | 2019-2025 | |
| Genentech USA, INC. | $618.97 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $339.90 | 2019-2025 | Opdualag, Reblozyl |
| Merck Sharp & Dohme LLC | $331.75 | 2019-2020 | |
| Celgene Corporation | $244.51 | 2019-2025 | Reblozyl, Pomalyst |
| Pfizer INC. | $213.54 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $172.32 | 2019-2025 | Imfinzi, Tagrisso |
| Gilead Sciences, INC. | $154.05 | 2022-2025 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $147.09 | 2019-2023 | Imbruvica |
| Abbvie INC. | $138.43 | 2019-2025 | |
| Seagen INC. | $111.31 | 2019-2020 | |
| Genzyme Corporation | $107.86 | 2019-2025 | |
| Exelixis INC. | $88.65 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.86 | 2019-2020 | |
| Astellas Pharma US INC | $82.39 | 2019 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javed Imam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.